Sponsor: Janssen Research and Development, LLC
Sponsor Study ID: MonumenTAL-3
Study Title: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
CTO #: 103892
NCT Number: NCT05455320
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Multiple Myeloma
Study Objectives: The primary objective of this study is to compare the e ficacy of talquetamab SC in combination with daratumumab SC and pomalidomide (Tal-DP; Arm A) and talquetamab SC in combination with daratumumab SC (Tal-D; Arm C) with that of daratumumab SC in combination with pomalidomide and dexamethasone (DPd; Arm B) as assessed by PFS, respectively.